References
- The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report on the expert committee on the diagnosis and classi‐fication of diabetes mellitus. Diabetes Care 1997; 20: 1183–97
- Stahl M., Jørgensen L. G. M., Hyltoft petersen P., Brandslund I., De fine olivarius N., Borch‐johnsen K. Optimization of preanalytical condi‐tions and analysis of plasma glucose. 1. Impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus. Scand J Clin Lab Invest 2001; 61: 169–80
- Jørgensen L. G. M., Stahl M., Brandslund I., Hyltoft petersen P., Borch‐johnsen K., De fine olivarius N. Plasma glucose reference interval in a low‐risk population 2. Impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus. Scand J Clin Lab Invest 2001; 181–190, 61
- Hyltoft petersen P., Brandslund I., Jørgensen L. G. M., Stahl M., De fine olivarius N., Borch‐johnsen K. Evaluation of systematic and random factors in measurements of fasting plasma glu‐cose as the basis for analytical quality specifica‐tions in the diagnosis of diabetes. 3. Impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus. Scand J Clin Lab Invest 2001; 61: 191–204
- Stahl M., Brandslund I., Jørgensen L. G. M., Hyltoft petersen P., Borch‐johnsen K., De fine olivarius N. Can capillary whole blood glucose and ve‐nous plasma glucose measurements be used in‐terchangeably in diagnosis of diabetes mellitus?. Scand J Clin Lab Invest 2002; 62: 159–66
- Jørgensen L. G. M., Brandslund I., Stahl M., Hyltoft petersen P., Iversen S., Klitgaard N., De fine oli‐varius N. Upper reference limit, analytical qual‐ity specifications and clinical use of haemoglo‐bin A1C. Scand J Clin Lab Invest 2002; 62: 609–22
- Jørgensen L. G. M., Brandslund I., Hyltoft petersen P., De fine olivarius N., Stahl M. The effect of the new ADA and WHO guidelines on the num‐ber of diagnosed cases of diabetes mellitus. Clin Chem Lab Med 2003; 41: 1246–50
- Hyltoft petersen P., Fraser C. G., Kallner A., Kenny D., (. e. d. s. ). Strategies to Set Global Analytical Quality Specifications in Laboratory Medicine. Scan J Clin Lab Invest 1999; 59: 475–585
- Jørgensen L. G. M., Hyltoft petersen P., Brandslund I. The impact of variability in the risk of disease exemplified by diagnosing diabetes mellitus based on ADA and WHO criteria as gold stan‐dard. Int. J Risk Assessment and Management, 2005 in press.
- http://www.westgard.com/guest17.htm
- http://www.westgard.com/guest26.htm
- Von eyben F. E., Hyltoft petersen P., Blaabjerg O., Lindegaard madsen E. Analytical quality speci‐fications for serum lactate dehydrogenase isoenzyme 1 based on clinical goals. Clin Chem Lab Med 1999; 37: 553–61
- The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1C) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968–83
- Stratton I. M., Adler A. I., Neil A. W., Matthews D. R., Manley S. E., Cull C. A., Hadden D., Turner R. C. Holman RR on behalf of the UK Prospective Diabetes Study Group. BMJ 2000; 321: 405–12
- Fraser C. G. Interpretation of clinical chemistry laboratory data. Blackwell Scientific Publica‐tions. Oxford Edinburgh London Boston Palo Alto Melbourne, , et al, 1986; 179 pp